Recent data from multicentre randomized controlled clinical trials suggest that tight BP management has greater benefit than strict glucose control in patients with diabetes.
1,2 In recognition of this, the American Diabetes Association (echoing recommendations from the sixth and seventh Joint National Councils for Hypertension (JNC 6 and VII
3 ) recommends a goal BP o130/85 mm Hg for patients with diabetes. There is also evidence that management of BP in hypertensive populations is often suboptimal. 4 Using computer-based data retrieval similar to previous work from our group, 5, 6 we evaluated BP control and medication use to develop strategies to achieve improved BP control in a population of diabetic veterans.
All computerized health records in VANCHCS of pharmacologically treated diabetic patients were reviewed. Based on a preliminary review, we analysed records from July 1999 through December 2000 to comprise an 18-month review period. Paired BP readings were stratified by JNC VI criteria (in use at the time of the evaluation). Clinical characteristics, laboratory data, and pharmacy data were then retrieved for these patients. The study was approved by the Human Studies Subcommittee, VA Northern California Health Care System. Serum lipids, chemistries, and hemoglobin A1c (HbA1c), measured by routine clinical laboratory methods, were retrieved from the computerized database. Active prescriptions, assessed by ongoing refills or recently initiated prescriptions, were also retrieved from the computerized database. Blood pressure medications were classed by VA categories (thiazide diuretic, potassium sparing diuretic, loop diuretic, a-blocker, b-blocker, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and calcium channel blocker, and 'other (e.g., clonidine)'). For all analyses, angiotensin-converting enzyme inhibitor and angiotensin receptor blocker usage were grouped together as reninangiotensin system blockade (RAS blockade). Data are shown as mean7s.d. w 2 analysis was used for discontinuous variables, while Kruskal-Wallis oneway analysis of variance was used for comparing non-normative continuous variables among several groups. If an interaction was identified, Dunn's pairwise multiple comparison procedure was employed to assess significance. Po0.05 was considered significant. 7 Blood pressure data were available for 3731 (60.2% of all patients receiving antidiabetic medications during this time period) and stratified by JNC VI criteria into normal BP and hypertension using systolic X130 mm Hg and diastolic X85 mm Hg: 1068 (28.6%) were normotensive, 2013 (54%) had isolated systolic hypertension, 594 (15.9%) had combined hypertension, and 56 (1.5%) had isolated diastolic hypertension. The clinical characteristics and antihypertensive treatment patterns for these four groups are shown in Table 1 . Almost all patients had HbA1c measured, but only about 2/3 had LDL calculated; this in part reflects the prevalence of hypertriglyceridemia 4400 mg/dl which obviates the calculation of LDL. The two groups of patients with diastolic hypertension were significantly younger than those with normal diastolic readings; their LDLcholesterol was higher. HbA1c was also lower in those with normal diastolic pressures, but this was not statistically significant. Table 1 also shows the frequency of antihypertensive medication class use in the four patient groups. Approximately 4/5th of hypertensives were being treated with antihypertensive medications, indicating general recognition of the problem, but leaving room for improvement. Fewer than 2/3rd in each group were on RAS blockade therapy. Since RAS blockade is of particular benefit in patients with diabetes, 8 and its use had been encouraged by VA guidelines in place since 1998, a higher proportion was expected. The failure to achieve a higher proportion of RAS blockade is unexplained, but probably reflects a combination of factors, including intolerance to these agents, recent entry into our health care system, lack of awareness of guidelines by some providers, and the difficulty of addressing the multiple problems of diabetes mellitus in a primary care setting. For each patient group, most patients were on two or fewer antihypertensive agents. Again, since treatment with multiple agents is also of particular benefit in patients with diabetes, 1,2 and often necessary for BP control, more use of multiple agent therapy is probably needed. It follows that the residual hypertension probably represents undertreatment rather than refractory hypertension (Table 2) .
Our data show that hypertension is common among diabetic patients in a VA population. Although only about 60% of the patients had BP recorded (a potential limitation), it is unlikely that the patients who had their BP recorded were appreciably different from those individuals who did not. Other data, such as HbA1c and age were not different between those individuals who had BP recorded and those who did not (not shown). Furthermore, hypertension was not well controlled in over 2/3 of these patients, with uncontrolled systolic more prevalent than uncontrolled diastolic hypertension. While isolated systolic hypertension (ISH) is common in the elderly, one might expect that those patients who manifested diastolic hypertension (with or without systolic hypertension) would have more severe hypertension and more comorbidity than those who manifested ISH. Indeed, in our study, patients with diastolic hypertension (both combined hypertension as well as isolated diastolic hypertension) while younger had worse glycemic (as represented by HbA1c) and lipid (as represented by LDL-cholesterol) control.
In addition to incomplete BP recording, another potential limitation is medication adherence. Our computer system tracks prescription fills, but does not document actual medication use. While it is possible that patients may be receiving medications, but not using them, thus causing poor BP control, this is unlikely given the qualitative similarities between our, and others, data. Indeed, it could be argued that a 'closed' system like VA, where medication, laboratory and demographic data, and services are all centralized, provides an ideal environment to study 'real-world' patients, relatively free of financial and logistical constraints on these aspects of care.
Our data are consistent with other studies based on VA records; while BP control is achievable, it is not frequently accomplished. 9 The VA experience is not appreciably different from other populations in the US or in other industrialized countries. Canadian investigators report poorly controlled hypertensives; 13% of Canadian hypertensives have pressures o140/90 compared to 25% in the US. 10 This is especially marked among patients with diabetes, where 9% in Canada have pressures below 140/90, compared to 36% in the US. 10 French investigators report that 80% of diabetic patients managed by generalists are hypertensive. 11 Our diabetic patients are comparable in age and comorbidity to other veterans, as well as other populations of patients with diabetes, 11, 12 although having more men than more general populations.
Is hypertension more difficult to control in patients with diabetes, for either pathophysiological or behavioural reasons? Patients with diabetes are considered to have underlying vascular disease, as well as other complications of chronic diabetes. Difficulty in BP control might reflect these and other comorbidities. Adherence issues may reflect the need to take multiple medications for several distinct medical conditions, including underlying kidney or autonomic disease. On the other hand, the HOT and UKPDS studies demonstrate that BP control in diabetes can be achieved, 1, 2 and, in keeping with our data, emphasize that combination therapy may be needed to achieve this goal.
In conclusion, we found that suboptimal BP control in our diabetic patients most likely results from undertreatment. In addition, the computerized database provides an opportunity to notify providers that specific patients' BPs are not at goal, and to suggest that medications, in particular RAS blockade, be modified or instituted. The database can also help remind clinicians to be cautious of potential exclusion criteria for RAS use. We also showed that a computerized database is an excellent resource for evaluating treatment strategies and outcomes. Such computer-based analyses play an increasingly important role as different medical practice models compete to deliver quality, cost-effective care.
